184 completed, 119 unknown, 33 not yet recruiting, 33 recruiting. 419 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 419 | Completed 184, Unknown 119, Not yet recruiting 33, Recruiting 33, Terminated 26, Withdrawn 13, Active not recruiting 7, Enrolling by invitation 3, Suspended 1 |
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy - Hepatitis B, Human Papilloma Virus | Phase 4 | Not yet recruiting | Eunice Dube | 2140 | 2027-01-30 | 2026-07-30 |
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| Tucatinib Continuation Study tucatinib - HER2-positive Breast Cancer, Cervical Cancer | Phase 4 | Not yet recruiting | Pfizer | 175 | 2026-11-06 | 2026-08-28 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| Assessing the Feasibility of Using Methylene Blue in Identifying Ureters During Colorectal Surgery Intravenous Methylene Blue, Methylene Blue Fluorescence Imaging System - Colorectal Cancer, Colorectal Surgery | Phase 4 | Not yet recruiting | Chinese University of Hong Kong | 20 | 2026-10-01 | 2026-10-06 |
| Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer | Phase 4 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 280 | 2026-09-15 | 2026-07-24 |
| Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients. Experimental - Elderly, Breast Cancer | Phase 4 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 794 | 2026-09-01 | 2026-09-03 |
| A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion HAIC, Donafenib + lenvatinib+apatinib, Sintilimab+camrelizumab+tislelizumab - Liver Cancer | Phase 4 | Not yet recruiting | Zhai Wenlong | 40 | 2026-08-30 | 2026-08-27 |
| Ferric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer Ferric Carboxymaltose (FCM), Iron Sucrose. - Gastric Cancer (GC), Iron Deficiency Anemia (IDA) | Phase 4 | Not yet recruiting | Zhaojian Niu,MD | 160 | 2026-08-01 | 2026-08-19 |
| A Phase IV Randomized Trial of Maxigesic® Versus Standard Analgesia After Radical Gastrectomy Acetaminophen (Newaminophen Premix), Maxigesic IV (acetaminophen/ibuprofen) - Stomach Neoplasms, Pain | Phase 4 | Not yet recruiting | Yonsei University | 160 | 2026-07-01 | 2026-07-07 |
| SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma Stereotactic Body Radiation Therapy (SBRT), QL1706 - HCC - Hepatocellular Carcinoma | Phase 4 | Not yet recruiting | Hebei Medical University Fourth Hospital | 36 | 2026-07-01 | 2026-06-25 |
| A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer Iparomlimab and Toripalimab, Bevacizumab, Gemcitabine (1000 mg/m2) - Biliary Tract Cancer (BTC) | Phase 4 | Recruiting | Xianglin Yuan | 32 | 2026-06-10 | 2026-09-15 |
| Transversus Abdominis Plane and Rectus Sheath Block for Robotic Colectomy Ropivacaine, Saline - Rectus Sheath Block, Transversus Abdominis Plane Block | Phase 4 | Not yet recruiting | Tri-Service General Hospital (TSGH) | 90 | 2026-06-01 | 2026-06-03 |
| A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma Iparomlimab and Tuvonralimab (QL1706) - Gastric Cancer (Diagnosis), Gastric Cancer (GC) | Phase 4 | Not yet recruiting | Huazhong University of Science and Technology | 55 | 2026-06-01 | 2026-03-30 |
| A Prospective Non-randomized Controlled Interventional Study on the Effect of Shouhui Tongbian Capsules Combined With Pancreatin Enteric-coated Capsules on Pancreatic Exocrine Function in Patients After Curative Resection for Pancreatic Cancer Shouhui Tongbian Capsules, Pancreatin Enteric-Coated Capsules - Pancreatic Cancer | Phase 4 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 80 | 2026-05-01 | 2026-04-29 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing Esomeprazole (Intravenous), Esomeprazole (Oral), Sucralfate Suspension - Early Gastric Cancer, Gastric Dysplasia | Phase 4 | Not yet recruiting | LanZhou University | 120 | 2026-04-20 | 2026-03-23 |
| RCT Comparing Reduced-port Robotic and Conventional Laparoscopic Subtotal Gastrectomy conventional laparoscopy gastrectomy group (Port > 3), reduced-port robotic group (Port ≤ 3) - Gastric Cancer | Phase 4 | Not yet recruiting | Yonsei University | 538 | 2026-04-01 | 2026-03-12 |
| Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant Atezolizumab, Bevacizumab, Y^90 Radioembolization - Hepatocellular Carcinoma | Phase 4 | Recruiting | Icahn School of Medicine at Mount Sinai | 40 | 2026-03-26 | 2026-07-28 |
| Next Generation STAR-TREC (NG-ST) - Organ Preservation in Early Rectal Cancer Capecitabine + Radiotherapy, Total Mesorectal Excision (TME) - Rectal Cancer | Phase 4 | Not yet recruiting | Vastra Gotaland Region | 90 | 2026-03-12 | 2026-03-19 |
Showing 20 of 419. Sign in to see all of them.
Colorectal Neoplasms (106) · Carcinoma, Hepatocellular (105) · Stomach Neoplasms (66) · Pancreatic Neoplasms (46) · Liver Neoplasms (39) · Colonic Neoplasms (38) · Esophageal Neoplasms (28) · Rectal Neoplasms (22) · Neoplasms (14) · Neoplasm Metastasis (13) · Gastrointestinal Neoplasms (12) · Breast Neoplasms (11) · Bile Duct Neoplasms (10) · Gastrointestinal Stromal Tumors (10) · Recurrence (10)
Digestive System Diseases (417) · Neoplasms by Site (413) · Neoplasms (405) · Gastrointestinal Diseases (252) · Gastrointestinal Neoplasms (242) · Intestinal Diseases (166) · Intestinal Neoplasms (157) · Colonic Diseases (144) · Neoplasms by Histologic Type (135) · Liver Diseases (125) · Neoplasms, Glandular and Epithelial (125) · Rectal Diseases (122) · Carcinoma (117) · Adenocarcinoma (110)
Oxaliplatin (18) · Capecitabine (17) · Fluorouracil (17) · Bevacizumab (16) · Sorafenib (10) · Irinotecan (8) · Leucovorin (8) · Esomeprazole (7) · Radiofrequency Ablation (7) · Bismuth (6) · Cisplatin (6) · Gemcitabine (6) · Morphine (6) · Propofol (6) · Amoxicillin (5)
Sun Yat-sen University (20) · Hoffmann-La Roche (10) · Fudan University (9) · Seoul National University Hospital (7) · Taipei Veterans General Hospital, Taiwan (7) · Yonsei University (7) · Xijing Hospital of Digestive Diseases (6) · Asan Medical Center (5) · Helsinki University Central Hospital (5) · Herlev Hospital (5) · Kaohsiung Medical University Chung-Ho Memorial Hospital (5) · Novartis Pharmaceuticals (5) · Pfizer (4) · RenJi Hospital (4) · Shandong Cancer Hospital and Institute (4)
China (104) · United States (66) · South Korea (33) · Taiwan (25) · France (17) · Spain (17) · Denmark (16) · Canada (12) · Netherlands (12) · Sweden (12) · Germany (10) · Italy (10) · United Kingdom (9) · Japan (8) · Switzerland (8)
Jinming Yu, Ph.D, M.D (3) · Katsunori Furukawa, MD (3) · Ming-Chih Hou, MD (3) · Anton Bermont, MD (2) · Austin G Acheson, MD FRCS (2) · Egidijus Semenas, MD, PhD (2) · Huang He, MD (2) · Julia LeBlanc, MD, MPH (2) · Marian Hajduch, MD PhD (2) · Markus Joerger, MD PhD (2)
PMID 11981766, PMID 12049862, PMID 12091661, PMID 12540794, PMID 37526194, PMID 10022643, PMID 10343249, PMID 10536559, PMID 10950834, PMID 11156645, PMID 11256129, PMID 11822956, PMID 11857360, PMID 12127688, PMID 12170403, PMID 12865912, PMID 1305308, PMID 13197542, PMID 14562011, PMID 14570648, PMID 14644354, PMID 14762851, PMID 1479177, PMID 15044883, PMID 15470215, PMID 15488052, PMID 15508094, PMID 15645403, PMID 15738894, PMID 15749627, PMID 15761078, PMID 15817555, PMID 15818423, PMID 15888773, PMID 15901026, PMID 15915027, PMID 16266222, PMID 16421419, PMID 1665400, PMID 16927929, PMID 16937471, PMID 16961802, PMID 17230616, PMID 17239480, PMID 17350947, PMID 17479030, PMID 17627902, PMID 17707751, PMID 17767471, PMID 17919374
2014 (3), 2019 (3), 2025 (3), 2008 (2), 2009 (1), 2016 (1), 2017 (1), P30CA014599 (1), P30CA046934 (1), R01CA091912 (1), U24CA086368 (1)